UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I. ...

SEL-212 for Chronic Refractory Gout - SEL-212 addresses a $1B+ chronic refractory gout market with high unmet need[5,15] - In a Phase 2 dose ranging study, 66% (21/32) of patients achieved SUA levels <6 mg/dL after 20 weeks of once-monthly SEL-212 treatment[17,18] - The company is conducting a head-to-head trial (COMPARE) of SEL-212 against pegloticase in chronic refractory gout patients, with approximately 150 patients enrolled[5,32] - Top-line data from the COMPARE trial is expected in 3Q 2020, and a Phase 3 pivotal program against placebo is planned for 2H 2020[5,64] ImmTOR Platform in Gene Therapy - The company's ImmTOR platform aims to mitigate Neutralizing Antibody (Nab) formation, potentially enabling re-dosing of AAV gene therapies[5] - Preclinical studies suggest ImmTOR can induce antigen-specific immune tolerance, preventing NAb development in mice treated with ImmTOR+AAV vector[42] - A license agreement with AskBio includes upfront payments of $7 million and potential clinical and sales milestone payments of $237 million for Pompe disease[50] - The company expects to commence a human POC trial under the AskBio collaboration in 4Q 2020[64] Financial Status - As of March 31, 2020, the company had $74.264 million in cash, cash equivalents, marketable securities, and restricted cash[61]

Selecta Biosciences, Inc. (SELB) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Elona Kogan - General Counsel & Corporate Secretary Bradford Dahms - CFO, Principal Financial Officer & Principal Accounting Officer Carsten Brunn - CEO, President & Director Kei Kishimoto - Chief Scientific Officer Conference Call Participants Ellie Merle - Cantor Fitzgerald & Co. Raju Prasad - William Blair & Company Yun Zhong - Janney Montgomery Scott John Newman - Canaccord Genuity Difei Yang - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employer Identification No.) (State or other jurisdiction ...

O ato Selecta.. Biosciences Corporate Presentation April 2 0 2 0 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate sup ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) | Delawar | | --- | Delaware 26-1622110 (I.R.S. Employer ...

Selecta Biosciences, Inc. (SELB) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Elona Kogan - General Counsel Carsten Brunn - President and Chief Executive Officer Brad Dahms - Chief Financial Officer Kei Kishimoto - Chief Scientific Officer Conference Call Participants Ellie Merle - Cantor Fitzgerald Raju Prasad - William Blair Chad Messer - Needham & Company John Newman - Canaccord Yun Zhong - Janney Difei Yang - Mizuho Securities USA Operator Good morning and welcome to ...

O ရှိ Selecta.. Biosciences Corporate Presentation February 2020 Nasdaq SELB Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate sup ...

O श्रे Selecta… Biosciences Corporate Presentation January 2020 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate supe ...

O ato Selecta… Biosciences Corporate Presentation November 2019 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate supe ...